AstraZeneca (NYSE:AZN) announced today that one of its COVID-19 vaccine candidate dosing regimens is 90% effective in preventing the virus.
Cambridge, United Kingdom-based AstraZeneca, working in collaboration with Oxford University, found the vaccine to be highly effective in preventing COVID-19 for subjects in the UK and Brazil, with no hospitalizations or severe cases of the disease reported in those who received the vaccine among 131 COVID-19 cases in the interim analysis, according to a news release.
Get the full story at our sister site, Drug Discovery & Development.